HCV: SOF/VEL/VOX yields sustained PRO gain

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • HCV treatment with sofosbuvir/velpatasvir (SOF/VEL) ± voxilaprevir (VOX) yields continued gain in patient-reported outcomes (PRO) after end of treatment.

Why this matters

  • PRO benefit was similar for SOF/VEL/VOX vs SOF/VEL.

Study design

  • PRO data from phase 3 POLARIS...